Latent Sarcomatous Consequences of Therapeutic Irradiation in Long-Term Brain Tumor Survivors: A Paradigm of Iatrogenic Complexity

Abstract

Introduction: Radiation therapy is an essential component of cancer treatment and has substantially improved survival for patients with many primary brain tumors. However, exposure to ionizing radiation can, rarely, result in the development of secondary malignancies years after treatment. Radiation-induced sarcoma (RIS) represents an uncommon but clinically important late complication of radiotherapy and has been described as an iatrogenic consequence of successful cancer treatment. RIS accounts for approximately 3% of all soft-tissue sarcomas and has been reported in approximately 0.03%–0.3% of patients exposed to therapeutic radiation. Reported 5-year overall survival remains poor, ranging from approximately 10% to 36%. Beyond its clinical significance, RIS illustrates the temporal complexity of therapeutic risk, in which a treatment that provides substantial immediate benefit may contribute to a rare adverse outcome many years later.

Objective: This study describes three cases of RIS arising after radiotherapy for primary intracranial tumors and examines their clinical characteristics, latency periods, histopathological features, management, and outcomes. The cases are additionally considered within broader perspectives of bioethics, survivorship medicine, biological time, and the long-term consequences of therapeutic interventions.
Methods: A retrospective case series was conducted involving three patients who developed RIS following radiotherapy for primary intracranial tumors, including pituitary adenoma, ependymoma, and meningioma. Clinical presentation, radiological findings, histopathological characteristics, treatment, latency between radiotherapy and sarcoma development, and clinical outcomes were systematically reviewed. The cases were also examined from a conceptual perspective to explore the implications of delayed treatment-related harm in long-term cancer survivorship.

Results: The patients were 19, 51, and 30 years old at the time of initial radiotherapy and subsequently developed RIS after latency periods of 9, 4, and 5 years, respectively. The secondary sarcomas were histologically distinct from the original tumors and comprised histiocytic sarcoma, undifferentiated high-grade sarcoma, and mesenchymal chondrosarcoma. All three tumors developed within previously irradiated fields. Surgical resection was performed in all patients, followed by adjuvant radiotherapy in two patients and adjuvant chemoradiotherapy in one. Post-RIS survival ranged from 1 to 2 years. One patient remained alive under regular follow-up at the time of reporting.

Conclusions: These cases highlight radiation-induced sarcoma as a rare but serious late complication of therapeutic irradiation in patients with longterm survival after primary brain tumors. The variable histological presentations and relatively short survival following RIS underscore the need for sustained clinical vigilance during survivorship. Long-term follow-up should consider the possibility of secondary malignancies, particularly when new or progressive lesions arise within previously irradiated fields. A multidisciplinary survivorship approach may facilitate earlier recognition, appropriate diagnostic evaluation, and timely management of delayed treatment-related complications. From a bioethical perspective, RIS also illustrates the importance of recognizing therapeutic risk as temporally extended rather than confined to the period immediately surrounding treatment.